Physician profile
John Ashley
NPI 1063411825
$23,624.57
in general payments reported to CMS, 2019-2025
37 companies · $3,330 in 2025
The $3,330 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,097 · 2020: $2,276 · 2021: $2,765 · 2022: $3,893 · 2023: $4,433 · 2024: $3,829 · 2025: $3,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,125.96 |
| Education | $466.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,941.54 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,196.40 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $2,183.96 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,785.11 | 2019-2025 | Ilumya, Winlevi, Blu-U |
| Novartis Pharmaceuticals Corporation | $1,655.67 | 2019-2025 | |
| Pfizer INC. | $1,604.89 | 2019-2025 | |
| Ucb, INC. | $1,540.89 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,283.32 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $1,219.26 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $1,126.06 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $682.50 | 2019-2023 | Adbry |
| Genzyme Corporation | $677.60 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $663.96 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Arcutis Biotherapeutics, INC. | $558.14 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $555.14 | 2022-2024 | Vtama |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $370.69 | 2019-2024 | |
| Incyte Corporation | $270.93 | 2021-2024 | Opzelura |
| Celgene Corporation | $187.75 | 2019 | |
| Galderma Laboratories, L.P. | $165.07 | 2019-2025 | Nemluvio |
| Organon LLC | $151.86 | 2025 | Vtama |
| Kyowa Kirin, INC. | $150.71 | 2020-2023 | Poteligeo |
| Genentech USA, INC. | $120.93 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $116.40 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $102.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.92 | 2022-2024 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $43.15 | 2019-2021 | |
| Organogenesis INC. | $27.53 | 2024 | |
| Fresenius Kabi USA, LLC | $23.24 | 2024 | Idacio |
| Krystal Biotech INC | $22.78 | 2023 | Vyjuvek |
| Janssen Pharmaceuticals, INC | $18.18 | 2023 | |
| Osiris Therapeutics INC. | $17.95 | 2019 | |
| Promius Pharma LLC | $15.48 | 2019 | |
| Sandoz INC. | $14.33 | 2019 | |
| Nabriva Therapeutics, Plc | $14.11 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.97 | 2021 | |
| Dermira, INC. | $13.11 | 2021 | |
| Merck Sharp & Dohme LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.